Cayston

Report
19 Pages
September 2018
Region: Global
Citeline
ID: 4775282

Drug Overview
Cayston is an inhalable formulation of the monobactam antibacterial aztreonam and was developed by Gilead.

It inhibits cell wall synthesis in aerobic Gram-negative bacteria, including Pseudomonas aeruginosa, one of the most common pathogens found in patients with cystic fibrosis.

Treatment with Cayston requires nebulization of the aztreonam solution, and the recommended dosing is three times daily.

CONTENTS

OVERVIEW

Drug Overview
Product Profiles
Cayston : Cystic fibrosis

LIST OF FIGURES

Figure 1: Cayston for cystic fibrosis – SWOT analysis
Figure 2: The authors drug assessment summary of Cayston for cystic fibrosis
Figure 3: The authors drug assessment summary of Cayston for cystic fibrosis
Figure 4: Cayston sales for cystic fibrosis across the US and five major EU markets, by country, 2016–25

LIST OF TABLES

Table 1: Cayston drug profile
Table 2: Cayston Phase III data in cystic fibrosis
Table 3: Cayston sales for cystic fibrosis across the US and five major EU markets, by country ($m), 2016–25

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€9668EUR$10,000USD£8,304GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€47373EUR$49,000USD£40,691GBP

Table of Contents

Related Topics

Related Reports

Inhaled Antibiotics Global Market Report 2024

Aztreonam Injection Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Product Type

Protein 50S ribosomal subunit inhibitors - Pipeline Insight, 2024

Antibiotic Drug Resistance. Edition No. 1

21st Century Challenges in Antimicrobial Therapy and Stewardship